Antimicrobial stewardship in Spain: Programs for Optimizing the use of Antibiotics (PROA) in Spanish hospitals.
Juan P Horcajada, Santiago Grau, José Ramón Paño-Pardo...
https://pubmed.ncbi.nlm.nih.gov/30250829/Actively Recruiting
Led by Maria Espinosa Perez · Updated on 2026-07-06
250
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating whether combining rapid multiplex molecular microbiology results with specific clinical and laboratory criteria in an antimicrobial stewardship program improves antimicrobial use in hospitalized adults receiving high-impact antimicrobial therapy. This study compares a new stewardship strategy integrating these rapid diagnostic results against the standard antimicrobial stewardship practice currently used in the hospital. The goal is to see if this combined approach can reduce antimicrobial exposure duration, improve treatment appropriateness, and affect important clinical outcomes such as hospital readmission, ICU admission, infection recurrence, mortality, and healthcare costs. Participants receive antimicrobial management according to the stewardship strategy assigned to their hospital unit, which is randomized in a cluster crossover design. The experimental strategy involves real-time review of multiplex molecular microbiology results integrated with predefined criteria to guide antimicrobial optimization. The comparator is the standard stewardship strategy based on routine clinical and microbiological information. After one period with each strategy and a washout, hospital units switch strategies to serve as their own controls. During the trial, participants undergo molecular microbiology testing and routine clinical and laboratory assessments as part of standard hospital care when needed. Researchers track antimicrobial exposure, treatment appropriateness, safety events, and clinical outcomes including ICU admission, hospital readmission, infection recurrence, mortality, and healthcare costs. The primary outcome measured is the duration of exposure to high-impact antimicrobial therapy up to 30 days after therapy initiation. Secondary outcomes include mortality, adverse events, ICU admission, readmission, infection recurrence, and healthcare costs within specified timeframes.
CONDITIONS
Molecular Microbiology- Guided Antimicrobial Stewardship Versus Standard Stewardship in Hospitalized Patients
M
María Espinosa Pérez, MD
S
Sergio Padilla Urrea, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Maria Espinosa Perez
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Varies by participant during the study period
Participants receive antimicrobial management according to the stewardship strategy assigned to their hospital unit during the first study period.
Duration - Varies by participant
A washout period is implemented to minimize carry-over effects before switching stewardship strategies.
Duration - Varies by participant during the study period
Participants receive antimicrobial management according to the alternative stewardship strategy assigned to their hospital unit during the second study period.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Juan P Horcajada, Santiago Grau, José Ramón Paño-Pardo...
https://pubmed.ncbi.nlm.nih.gov/30250829/Caitlin N Murphy, Randal Fowler, Joan Miquel Balada-Llasat...
https://pubmed.ncbi.nlm.nih.gov/32350043/Anne-Clotilde Moy, Antoine Kimmoun, Thomas Merkling...
https://pubmed.ncbi.nlm.nih.gov/37709201/Anna Maria Peri, Mark D Chatfield, Weiping Ling...
https://pubmed.ncbi.nlm.nih.gov/38676943/Tanja Holma, Jukka Torvikoski, Nathalie Friberg...
https://pubmed.ncbi.nlm.nih.gov/34350523/Virve I Enne, Susan Stirling, Julie A Barber...
https://pubmed.ncbi.nlm.nih.gov/39961847/Maria Espinosa Perez
Lead Sponsor